Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes Body Care Children Complications Defeat Diabetes Foundation Drugs    » ACE Inhibitor    » Actos    » Alternative Medicine    » Aspirin    » Avandia    » Byetta    » Drugs    » Exenatide    » Glargine    » Glucophage    » Insulin    » Januvia    » Lantus    » Liraglutide    » Metformin    » Recall    » Research    » Rosiglitazone    » Self-Management    » Statins    » Sulfonylureas    » Victoza Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

Drugs » Januvia

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

FDA Approves Diabetes and Cholesterol-Lowering Drug Combo: Juvisync® Posted: Sunday, October 09, 2011

Known as Juvisync (Merck), the new medication combines sitagliptin (Januvia, Merck), a dipeptidyl peptidase-4 (DPP-4) inhibitor used for glycemia control, with the cholesterol-lowering simvastatin.

FDA Approves New DPP-IV Inhibitor: Tradjenta (Linagliptin) Posted: Sunday, May 08, 2011

A new prescription medication Tradjenta (linagliptin) has gained FDA approval for the treatment of adult Type 2 diabetes. Tradjenta will compete with two other drugs in the same family, Onglyza and Januvia.

Search for Diabetes "Cure" Focuses on Beta-Cell Regeneration Posted: Tuesday, December 28, 2010

A simple strategy of just combining two FDA approved drugs (Januvia® + Prevacid®) may restore normoglycemia.

EASD: Pioglitazone-Sitagliptin Combination Achieves Durable Glycemic Control Posted: Sunday, October 03, 2010

Adding 50 mg of sitagliptin (Januvia) to pioglitazone (Actos) allowed patients with Type 2 diabetes to achieve sustained glycemic control, a yearlong trial showed.

FDA Issues Caution for Januvia and Janumet for Acute Pancreatitis Posted: Wednesday, September 30, 2009

U.S. health officials said on Friday they suspect Merck & Co., Inc.'s blockbuster diabetes drug Januvia may be linked to serious cases of inflamed pancreas, but company officials disputed the connection.

DPP-IV Inhibitors and Increased GLP-1 Levels May Increase Pancreatitis Risk -- Metformin Can Negate Adverse Effects Posted: Tuesday, May 12, 2009

A drug widely used to treat Type 2 diabetes may have unintended effects on the pancreas that could lead to a form of low-grade pancreatitis in some patients and a greater risk of pancreatic cancer in long-term users, according to researchers at UCLA , but the adverse effects can be negated when combined with an older diabetes drug.

Type 2 Diabetes Drug Increases Pancreatitis and Pancreatic Cancer Risk Posted: Wednesday, May 06, 2009

A common drug used to lower blood sugar in type 2 diabetics has been observed to increase risk of pancreatitis, and is believed to also increase long-term pancreatic cancer risk.

EASD: Byetta Wins In Head to Head Trial Over Januvia In Postprandial Glucose Posted: Wednesday, September 17, 2008

In a month-long head-to-head trial, the incretin mimetic exenatide (Byetta) reduced postprandial glucose in type 2 diabetes more than did sitagliptin (Januvia), an oral DPP-4 inhibitor, researchers reported.

Januvia/Byetta Becoming First and Second-Line Therapy for Type 2 Diabetes Posted: Wednesday, September 10, 2008

New research reports that Januvia is currently prescribed most often as a third- or later-line of therapy for the treatment of type 2 diabetes.

Sitagliptin (Januvia) Plus a Sulfonylurea Increases Risk for Hypoglycemia Posted: Wednesday, February 27, 2008

The FDA approved safety labeling revisions for sitagliptin tablets (Januvia; Merck & Co, Inc) to advise of the risk for hypoglycemia.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.